Clinical Trials Logo
  1. Home
  2. Breast Cancer
  3. NCT00241462
  4. Details
NCT00241462 Clinical Trial

Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients

Breast Cancer Clinical Trial

— FORUM  

Official title:
Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00241462
Other study ID # D6997-NL-001
Secondary ID FORUM
Status Terminated
Phase Phase 4
First received October 18, 2005
Last updated April 21, 2009
Start date June 2005
Est. completion date December 2009

Study information
Verified date April 2009
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Observational

Clinical Trial Summary

The purpose of this study is to identify which patients, receiving Faslodex within the approved label, benefit most from Faslodex treatment.

Recruitment information / eligibility
Status Terminated
Enrollment 150
Est. completion date December 2009
Est. primary completion date
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Postmenopausal

- Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status

- Patient had a recurrence during or after adjuvant anti-oestrogen treatment or progression of the disease during anti-oestrogen treatment

Exclusion Criteria:

- Life threatening metastases

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Netherlands Research Site Alkmaar
Netherlands Research Site Almelo
Netherlands Research Site Almere
Netherlands Research Site Amsterdam
Netherlands Research Site Apeldoorn
Netherlands Research Site Assen
Netherlands Research Site Bergen op Zoom
Netherlands Research Site Capelle Aan Den Ijssel
Netherlands Research Site Delft
Netherlands Research Site Delfzijl
Netherlands Research Site Doetinchem
Netherlands Research Site Dokkum
Netherlands Research Site Dordrecht
Netherlands Research Site Drachten
Netherlands Research Site Ede Gld
Netherlands Research Site Eindhoven
Netherlands Research Site Geldrop
Netherlands Research Site Gorinchem
Netherlands Research Site Hardenberg
Netherlands Research Site Heerenveen
Netherlands Research Site Heerlen
Netherlands Research Site Hellevoetsluis
Netherlands Research Site Hilversum
Netherlands Research Site Hoogeveen
Netherlands Research Site Leiden
Netherlands Research Site Leiderdorp
Netherlands Research Site Leidschendam
Netherlands Research Site Meppel
Netherlands Research Site Nieuwegein
Netherlands Research Site Oss
Netherlands Research Site Roermond
Netherlands Research Site Rotterdam
Netherlands Research Site S-Gravenhage
Netherlands Research Site Stadskanaal
Netherlands Research Site Terneuzen
Netherlands Research Site Tilburg
Netherlands Research Site Utrecht
Netherlands Research Site Vlaardingen
Netherlands Research Site Winschoten
Netherlands Research Site Winterswijk
Netherlands Research Site Zeist
Netherlands Research Site Zevenaar
Netherlands Research Site Zwolle

Sponsors (1)
Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Netherlands, 

See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A